ASCCP Sydney 2017 The Nonavalent Vaccine (3520)
The nonavalent HPV Vaccine, also known as Gardasil 9 (Merck, USA), was approved in the US in December 2014. This vaccine provides protection against 5 additional HPV types and is believed to cover ~90% of high risk HPV types associated with invasive cervical cancer. Phase III clinical trial data demonstrate clinically significant protection against these 5 additional types as well as a considerable reduction in abnormal screening tests and subsequent treatment. Recently, the FDA approved a two doses series for children ages 9-14. This presentation will review the clinical trial data that led to the approval of Gardasil 9 and address questions about the vaccine including 1) Should we consider gender specific vaccines (ie, Gardasil for boys and Gardasil 9 for girls)?, 2) Should we consider vaccinating with Gardasil 9 if an individual has been previously vaccinated against Gardasil?, and 3) Is it possible to move to a one dose series?
*DISCLOSURE: Dr. Huh serves on the publications committee for Merck Vaccines (Gardasil 9)
